Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) shares traded down 8.8% during mid-day trading on Friday . The stock traded as low as C$0.78 and last traded at C$0.83. 85,948 shares changed hands during mid-day trading, an increase of 79% from the average session volume of 48,036 shares. The stock had previously closed at C$0.91.
Medicenna Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. The company has a 50-day moving average of C$1.00 and a 200-day moving average of C$1.17. The firm has a market capitalization of C$62.10 million, a price-to-earnings ratio of -2.29 and a beta of 1.21.
Medicenna Therapeutics Company Profile
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Featured Stories
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
